These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29318941)

  • 1. PEG-modification on the endo-position of an antisense oligonucleotide increases tumor accumulation via the EPR effect.
    Hagiwara K; Kurihara K; Honma M; Yamamoto J; Shinohara F
    J Biomater Sci Polym Ed; 2018 Mar; 29(4):448-459. PubMed ID: 29318941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biophysical properties of tetravalent PEG-conjugated antisense oligonucleotide.
    Rahman Chowdhury T; Taufiq T; Ishida K; Ariful Islam M; Kasahara Y; Osawa T; Obika S
    Bioorg Med Chem; 2023 Jan; 78():117149. PubMed ID: 36587552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
    Springate CM; Jackson JK; Gleave ME; Burt HM
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):239-47. PubMed ID: 15864591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of antisense oligonucleotide functionalized core-shell nanoparticles loaded with α-tocopherol succinate.
    Kilicay E; Karahaliloglu Z; Alpaslan P; Hazer B; Denkbas EB
    J Biomater Sci Polym Ed; 2017 Oct; 28(15):1762-1785. PubMed ID: 28696185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides.
    Wang D; Wang Q; Wang Y; Chen P; Lu X; Jia F; Sun Y; Sun T; Zhang L; Che F; He J; Lian L; Morano G; Shen M; Ren M; Dong SS; Zhao JJ; Zhang K
    Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2113180119. PubMed ID: 35858356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
    Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer.
    Heger Z; Polanska H; Krizkova S; Balvan J; Raudenska M; Dostalova S; Moulick A; Masarik M; Adam V
    Colloids Surf B Biointerfaces; 2017 Feb; 150():131-140. PubMed ID: 27907860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
    J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
    Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
    J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and delivery of splice-correction antisense oligonucleotides by amino acid modified polyethylenimine.
    Zaghloul EM; Viola JR; Zuber G; Smith CI; Lundin KE
    Mol Pharm; 2010 Jun; 7(3):652-63. PubMed ID: 20128628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of 2'-O-(2-N-Methylcarbamoylethyl) Nucleotides in RNase H-Dependent Antisense Oligonucleotides.
    Masaki Y; Iriyama Y; Nakajima H; Kuroda Y; Kanaki T; Furukawa S; Sekine M; Seio K
    Nucleic Acid Ther; 2018 Oct; 28(5):307-311. PubMed ID: 30020852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
    He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
    Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of a Novel Liposomal DDS by Manipulating Pharmacokinetics and Intracellular Trafficking for Drug Therapy and Nucleic Acid Medicine].
    Hatakeyama H
    Yakugaku Zasshi; 2018; 138(5):591-598. PubMed ID: 29709998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
    Hong D; Kurzrock R; Kim Y; Woessner R; Younes A; Nemunaitis J; Fowler N; Zhou T; Schmidt J; Jo M; Lee SJ; Yamashita M; Hughes SG; Fayad L; Piha-Paul S; Nadella MV; Mohseni M; Lawson D; Reimer C; Blakey DC; Xiao X; Hsu J; Revenko A; Monia BP; MacLeod AR
    Sci Transl Med; 2015 Nov; 7(314):314ra185. PubMed ID: 26582900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.
    Gao JQ; Eto Y; Yoshioka Y; Sekiguchi F; Kurachi S; Morishige T; Yao X; Watanabe H; Asavatanabodee R; Sakurai F; Mizuguchi H; Okada Y; Mukai Y; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
    J Control Release; 2007 Sep; 122(1):102-10. PubMed ID: 17628160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic oligonucleotides with polyethylene glycol modifications.
    Winkler J
    Future Med Chem; 2015; 7(13):1721-31. PubMed ID: 26465713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive delivery of oligonucleotide by penetratin-modified polyplexes to inhibit protein expression of intraocular tumor.
    Tai L; Liu C; Jiang K; Chen X; Wei G; Lu W; Pan W
    Nanomedicine; 2017 Aug; 13(6):2091-2100. PubMed ID: 28435135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
    Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
    J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.